INAB
$2.00+0.28 (+16.28%)
Market ClosedAs of Mar 20, 8:00 PM UTC
IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell product candidates for the treatment of cancer and autoimmune diseases.
Historical Price
Price (Line)
50-Day SMA
200-Day SMA
Synthesizing Whystock Narrative...
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$2.00
Potential Upside
5%
Whystock Fair Value$2.10
Price
UndervaluedFair ValueOvervalued
Fundamentals
IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell product candidates for the treatment of cancer and autoimmune diseases. Its products include INB-400, which i...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$19.69M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.00
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Average efficiency. Growth may require heavy reinvestment.
-201.47%
Quick Ratio
Pristine liquidity. Sufficient cash to cover all near-term obligations.
6.91
Recent News
No recent news found.